Skip to content

Jasper Therapeutics

5 viewers · 30d

Total raised

$132.0M

+$132.0M this year

1 filing since 2026 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $132.0M
ROUNDS
1
INVESTORS
40
FOUNDED
N/A
HQ
Redwood City, CA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
5

AI overview

Updated

Jasper Therapeutics is a clinical-stage biotechnology company in Redwood City, California developing antibody therapies for immune-mediated and rare diseases. Its lead legacy asset, briquilimab, is an aglycosylated monoclonal antibody that blocks stem cell factor from binding the KIT (CD117) receptor, depleting mast cells and hematopoietic stem cells through apoptosis. In July 2026 Jasper acquired Kira Pharmaceuticals in an all-stock deal, adding a complement-inhibition and B-cell pipeline and a second site in Cambridge, Massachusetts. The company was incorporated in Delaware in 2018 and went public in 2021 via a merger with Amplitude Healthcare Acquisition Corporation.

What sets it apart

Briquilimab is a targeted anti-KIT antibody that removes the mast cells causing the inflammatory response rather than suppressing downstream mediators, with a demonstrated efficacy and safety profile across more than 160 dosed subjects and healthy volunteers.

Funding history

1 round
EquityJul 21, 2026
Form D
+$132.0M$132.0M total

Latest SEC filings

via EDGAR · CIK 0001788028
Form D · Jul 21, 2026NewView on EDGAR

Products

1 tracked

Briquilimab

Monoclonal antibody therapeutic

An investigational aglycosylated monoclonal antibody targeting KIT (CD117) that blocks stem cell factor signaling and depletes mast cells and hematopoietic stem cells via apoptosis, in development for chronic urticaria and progressing toward a pre-BLA meeting in severe combined immunodeficiency (SCID).

  • Targets KIT (CD117) and blocks stem cell factor binding
  • Aglycosylated antibody format
  • Depletes mast cells through apoptosis
  • Subcutaneous dosing evaluated in the BEACON Phase 1b/2a study in chronic spontaneous urticaria

Links

WebsiteLinkedInSEC EDGAR filings